Veliflapon is primarily investigated for its potential therapeutic applications in inflammatory conditions, particularly those involving the 5-lipoxygenase pathway. It acts as a selective inhibitor of 5-lipoxygenase, an enzyme that plays a key role in the synthesis of leukotrienes, which are inflammatory mediators. By inhibiting this enzyme, Veliflapon may help reduce inflammation and associated symptoms in conditions such as asthma, atherosclerosis, and other inflammatory diseases. Research has also explored its use in cardiovascular diseases, where leukotrienes contribute to plaque formation and arterial inflammation. Its ability to modulate inflammatory pathways makes it a candidate for further development in treating chronic inflammatory and autoimmune disorders.